• Jun. 25, 2019 (PDF/169KB)R&D

  Poxel and Sumitomo Dainippon Pharma Announce Second Positive Top-Line Results for Imeglimin Phase 3 Trial (TIMES 3) in Japan for the Treatment of Type 2 Diabetes

• Jun. 18, 2019 (PDF/87KB)Products

  Sumitomo Dainippon Pharma and Nitto Denko Announce the Approval of Atypical Antipsychotic LONASEN Tape in Japan

• Jun. 17, 2019 (PDF/241KB)Corporate

  Sumitomo Dainippon Pharma announces Personnel Changes

• Jun. 13, 2019 (PDF/82KB)R&D

  Sumitomo Dainippon Pharma announces Changes to Agreement on Joint Development of Treatments for Eye Diseases Using iPS Cell-derived Retinal Pigment Epithelial Cells in Japan

• Jun. 07, 2019 (PDF/127KB)R&D

  Sumitomo Dainippon Pharma Announces Recommendation to Continue Phase 3 CanStem303C Study of Investigational Anti-Cancer Agent Napabucasin in Patients with Colorectal Cancer Following Interim Analysis

more